Analysis Of The Effectiveness Of Total Neoadjuvant Therapy In The Treatment Of Patients With Pancreatic Cancer

Abstract

Pancreatic cancer remains one of the most aggressive and lethal malignancies in modern oncology and continues to pose a major clinical challenge worldwide. Pancreatic ductal adenocarcinoma (PDAC) accounts for more than 90% of all pancreatic malignancies and is characterized by rapid disease progression, early metastatic spread, and resistance to many conventional treatment modalities. Despite representing a smaller proportion of overall cancer incidence, pancreatic cancer ranks among the leading causes of cancer-related mortality, with five-year survival rates remaining below 15% in most populations. This unfavorable prognosis reflects a combination of late diagnosis, complex tumor biology, and limited therapeutic effectiveness